These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
413 related articles for article (PubMed ID: 22391104)
1. Positron emission tomography/computed tomography imaging of residual skull base chordoma before radiotherapy using fluoromisonidazole and fluorodeoxyglucose: potential consequences for dose painting. Mammar H; Kerrou K; Nataf V; Pontvert D; Clemenceau S; Lot G; George B; Polivka M; Mokhtari K; Ferrand R; Feuvret L; Habrand JL; Pouysségur J; Mazure N; Talbot JN Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):681-7. PubMed ID: 22391104 [TBL] [Abstract][Full Text] [Related]
2. [18F]-Fluoromisonidazole positron emission tomography/computed tomography visualization of tumor hypoxia in patients with chordoma of the mobile and sacrococcygeal spine. Cheney MD; Chen YL; Lim R; Winrich BK; Grosu AL; Trofimov AV; Depauw N; Shih HA; Schwab JH; Hornicek FJ; DeLaney TF Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1030-6. PubMed ID: 25539367 [TBL] [Abstract][Full Text] [Related]
3. Detection of hypoxia with 18F-fluoromisonidazole (18F-FMISO) PET/CT in suspected or proven pancreatic cancer. Segard T; Robins PD; Yusoff IF; Ee H; Morandeau L; Campbell EM; Francis RJ Clin Nucl Med; 2013 Jan; 38(1):1-6. PubMed ID: 23242037 [TBL] [Abstract][Full Text] [Related]
4. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Rajendran JG; Wilson DC; Conrad EU; Peterson LM; Bruckner JD; Rasey JS; Chin LK; Hofstrand PD; Grierson JR; Eary JF; Krohn KA Eur J Nucl Med Mol Imaging; 2003 May; 30(5):695-704. PubMed ID: 12632200 [TBL] [Abstract][Full Text] [Related]
5. Comparison of Hypermetabolic and Hypoxic Volumes Delineated on [ Thureau S; Modzelewski R; Bohn P; Hapdey S; Gouel P; Dubray B; Vera P Mol Imaging Biol; 2020 Jun; 22(3):764-771. PubMed ID: 31432388 [TBL] [Abstract][Full Text] [Related]
6. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. Lee NY; Mechalakos JG; Nehmeh S; Lin Z; Squire OD; Cai S; Chan K; Zanzonico PB; Greco C; Ling CC; Humm JL; Schöder H Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):2-13. PubMed ID: 17869020 [TBL] [Abstract][Full Text] [Related]
7. The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy. Okamoto S; Shiga T; Yasuda K; Watanabe S; Hirata K; Nishijima KI; Magota K; Kasai K; Onimaru R; Tuchiya K; Kuge Y; Shirato H; Tamaki N Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2147-2154. PubMed ID: 27251644 [TBL] [Abstract][Full Text] [Related]
8. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer. Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733 [TBL] [Abstract][Full Text] [Related]
9. Radiosensitizing effect of irisquinone on glioma through the downregulation of HIF-1α evaluated by 18F-FDG and 18F-FMISO PET/CT. Wang H; Zhang Y; Yu W; Zhao X; Xue Y; Xu H Nucl Med Commun; 2016 Jul; 37(7):705-14. PubMed ID: 26963468 [TBL] [Abstract][Full Text] [Related]
10. Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AlF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model. Cheng Z; Wei R; Wu C; Qing H; Jiang X; Lu H; Chen S; Li X; Xu G; Ai H Nucl Med Commun; 2015 Sep; 36(9):914-21. PubMed ID: 25973694 [TBL] [Abstract][Full Text] [Related]
11. ¹⁸F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with ¹⁸F-FMISO. Chen L; Zhang Z; Kolb HC; Walsh JC; Zhang J; Guan Y Nucl Med Commun; 2012 Oct; 33(10):1096-102. PubMed ID: 22836736 [TBL] [Abstract][Full Text] [Related]
12. Multiparametric [18F]Fluorodeoxyglucose/ [18F]Fluoromisonidazole Positron Emission Tomography/ Magnetic Resonance Imaging of Locally Advanced Cervical Cancer for the Non-Invasive Detection of Tumor Heterogeneity: A Pilot Study. Pinker K; Andrzejewski P; Baltzer P; Polanec SH; Sturdza A; Georg D; Helbich TH; Karanikas G; Grimm C; Polterauer S; Poetter R; Wadsak W; Mitterhauser M; Georg P PLoS One; 2016; 11(5):e0155333. PubMed ID: 27167829 [TBL] [Abstract][Full Text] [Related]
13. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma. Kikuchi M; Yamane T; Shinohara S; Fujiwara K; Hori SY; Tona Y; Yamazaki H; Naito Y; Senda M Ann Nucl Med; 2011 Nov; 25(9):625-33. PubMed ID: 21720778 [TBL] [Abstract][Full Text] [Related]
14. A prospective clinical trial of tumor hypoxia imaging with 18F-fluoromisonidazole positron emission tomography and computed tomography (F-MISO PET/CT) before and during radiation therapy. Tachibana I; Nishimura Y; Shibata T; Kanamori S; Nakamatsu K; Koike R; Nishikawa T; Ishikawa K; Tamura M; Hosono M J Radiat Res; 2013 Nov; 54(6):1078-84. PubMed ID: 23589026 [TBL] [Abstract][Full Text] [Related]
15. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET. Cherk MH; Foo SS; Poon AM; Knight SR; Murone C; Papenfuss AT; Sachinidis JI; Saunder TH; O'Keefe GJ; Scott AM J Nucl Med; 2006 Dec; 47(12):1921-6. PubMed ID: 17138734 [TBL] [Abstract][Full Text] [Related]
16. Correlation of (18)F-fluoromisonidazole PET findings with HIF-1α and p53 expressions in head and neck cancer: comparison with (18)F-FDG PET. Norikane T; Yamamoto Y; Maeda Y; Kudomi N; Matsunaga T; Haba R; Iwasaki A; Hoshikawa H; Nishiyama Y Nucl Med Commun; 2014 Jan; 35(1):30-5. PubMed ID: 24121312 [TBL] [Abstract][Full Text] [Related]
17. Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Thorwarth D; Eschmann SM; Holzner F; Paulsen F; Alber M Radiother Oncol; 2006 Aug; 80(2):151-6. PubMed ID: 16920211 [TBL] [Abstract][Full Text] [Related]
18. Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor. Toyonaga T; Yamaguchi S; Hirata K; Kobayashi K; Manabe O; Watanabe S; Terasaka S; Kobayashi H; Hattori N; Shiga T; Kuge Y; Tanaka S; Ito YM; Tamaki N Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):611-619. PubMed ID: 27752745 [TBL] [Abstract][Full Text] [Related]
19. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer. Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091 [TBL] [Abstract][Full Text] [Related]
20. Assessment of biological parameters in head and neck cancer based on in vivo distribution of Cegla P; Kazmierska J; Gwozdz S; Czepczynski R; Malicki J; Cholewinski W Tumori; 2020 Feb; 106(1):33-38. PubMed ID: 31446858 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]